Transglutaminase 2 mRNA (TGM2 mRNA) (TGM2 mRNA)

Transglutaminase 2 (TG2) mRNA, encoded by the TGM2 gene, is a critical therapeutic target for diseases characterized by aberrant protein cross-linking and extracellular matrix (ECM) remodeling [1, 2]. TG2 is a pleiotropic enzyme that functions as a transamidase, GTPase, and protein scaffold, playing roles in cell adhesion, signal transduction, and apoptosis [3, 4]. In pathological states such as idiopathic pulmonary fibrosis (IPF) and chronic kidney disease, elevated TGM2 mRNA levels lead to excessive TG2 protein, which stabilizes the ECM through covalent cross-linking, driving tissue stiffening and scarring [14, 29]. In oncology, TGM2 mRNA overexpression is associated with epithelial-mesenchymal transition (EMT), metastasis, and resistance to chemotherapy and radiation [6, 33]. Targeting the mRNA directly via antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) offers a strategy to deplete the total pool of TG2 protein, thereby inhibiting both its enzymatic and non-enzymatic pro-disease functions [12, 30]. While clinical-stage inhibitors like GSK3915393 and ZED1227 currently target the TG2 protein, RNA-based modalities are being explored preclinically to achieve more comprehensive silencing of the TG2 pathway [22, 35].

Other names

Tissue transglutaminase mRNATG2 mRNATGM2 mRNATGase 2 mRNATransglutaminase C mRNA

RNA interference (siRNA), RNase H-mediated mRNA degradation (ASO), and translation inhibition to reduce total Transglutaminase 2 protein levels.